Aug 11, 2022

Partnership will help MMS expand its services and extend its leadership in data-focused clinical research services. Michael Barbella, Managing Editor08.11.22 Lindsay Goldberg , a family and founder-focused private equity firm, has completed an investment in  MMS Holdings Inc.  alongside MMS Founder and CEO Dr. Uma Sharma, who will maintain a significant ownership interest. MMS is a global, data-focused CRO. With more than 800 global colleagues across four continents, MMS couples a science-first approach with its customer service to provide the quality regulatory and data-focused services necessary to support high-impact clinical research and to facilitate successful new therapy approvals. “We are delighted to have found a private equity partner who both values our unique culture and who can help us scale our business, as we grow to be the best in class” said Sharma. “Lindsay Goldberg has decades of experience in actively building healthcare businesses and working collaboratively with founders. We are proud to have a partner with a shared vision and deep experience in successfully growing founder-led businesses.”   “We’re proud to partner with Dr. Sharma to help accelerate the growth of MMS, a leader in data-focused CRO services known internationally for its scientific approach and differentiated regulatory, biostatistics, data management, medical writing, and pharmacovigilance capabilities,” said Lindsay Goldberg Principal Peter Nurnberg. “We recognize that MMS’ globally cohesive culture is foundational to its reputation for exceptional customer service and we will continue to foster this customer-centric focus.”   Michael Dees, Managing Partner at Lindsay Goldberg, added, “Dr. Sharma’s team is delivering critical services to companies and thereby improving their chances of successful drug submissions. Through our partnership, we can help accelerate the company’s momentum and growth, while maintaining a focus on producing the highest quality, scientifically-sound deliverables.”   MMS is a data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Lindsay Goldberg is a private investment firm that focuses on partnering with families, founders and management teams seeking to actively build their businesses. Since 2001, Lindsay Goldberg has raised more than $17 billion of equity capital and has invested in over 50 platform companies and over 250 follow-on opportunities. The firm focuses on three industries that typically demonstrate resilience across economic cycles, including industrials, healthcare, and services (business, government, and financial services), in the United States, Canada, and Western Europe. Trending